Thromb Haemost 2011; 105(05): 750-751
DOI: 10.1160/TH11-02-0124
Invited Editorial Focus
Schattauer GmbH

Perioperative antiplatelet therapy: A knife-edged choice between thrombosis and bleeding still based on consensus rather than evidence

Karlheinz Peter
1   Baker IDI Heart and Diabetes Institute, Melbourne, Australia
3   Monash University, Melbourne, Australia
,
Paul S. Myles
2   Department of Anaesthesia and Perioperative Medicine, Alfred Hospital, Melbourne, Australia
3   Monash University, Melbourne, Australia
› Author Affiliations
Further Information

Publication History

Received: 23 February 2011

Accepted: 23 February 2011

Publication Date:
28 November 2017 (online)

 

Editorial Focus on: Korte et al. Thromb Haemost 2011; 105: 743-749.

 
  • References

  • 1 Weiser TG. et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008; 372: 139-144.
  • 2 Devereaux PJ. et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627-634.
  • 3 Korte W. et al. Peri-operative management of anti-platelet therapy in patients with coronary artery disease. Thromb Haemost 2011; 105: 743-749.
  • 4 Oscarsson A. et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104: 305-312.
  • 5 Straub A. et al. Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery. Thromb Haemost 2007; 97: 608-616.
  • 6 von Kanel R. et al. Effect of beta2-adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress. Am Heart J 2002; 144: 68-72.
  • 7 Priebe HJ. Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth 2004; 93: 9-20.
  • 8 Naesh O. et al. Platelet function in surgical stress. Thromb Haemost 1985; 54: 849-852.
  • 9 Beving H. et al. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996; 7: 80-84.
  • 10 Ferrari E. et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-459.
  • 11 Biondi-Zoccai GG. et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-2674.
  • 12 Chassot PG. et al. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99: 316-328.
  • 13 Sun JC. et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071.
  • 14 Burger W. et al. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257: 399-414.
  • 15 Vicenzi MN. et al. Coronary artery stenting and non-cardiac surgery--a prospective outcome study. Br J Anaesth 2006; 96: 686-693.
  • 16 Newsome LT. et al. Coronary artery stents: II. Peri-operative considerations and management. Anesth Analg 2008; 107: 570-590.
  • 17 Gasparyan AY. et al. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
  • 18 Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-227.
  • 19 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
  • 20 Zimmermann N. et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982-984.
  • 21 Cornelissen J. et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost 2006; 95: 476-482.
  • 22 Santilli F. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin ″resistance″. J Am Coll Cardiol 2009; 53: 667-677.
  • 23 Zurn CS. et al. ADP-receptor blockade: A case for personalised pharmacotherapy?. Thromb Haemost 2010; 103: 496-506.
  • 24 Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 2010; 103: 535-544.